Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
Simone I. Richardson, Frances Ayres, Nelia P. Manamela, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 21

Showing 21 citing articles:

Antiviral neutralizing antibodies: from in vitro to in vivo activity
Dennis R. Burton
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 720-734
Open Access | Times Cited: 61
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Craig Fenwick, Priscilla Turelli, Dongchun Ni, et al.
Nature Microbiology (2022) Vol. 7, Iss. 9, pp. 1376-1389
Open Access | Times Cited: 39
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31
Next-generation bNAbs for HIV-1 cure strategies
Angela I. Schriek, Yoann Aldon, Marit J. van Gils, et al.
Antiviral Research (2023) Vol. 222, pp. 105788-105788
Open Access | Times Cited: 12
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor
Kelsey A. Pilewski, Steven C. Wall, Simone I. Richardson, et al.
Cell Reports (2023) Vol. 42, Iss. 2, pp. 112044-112044
Open Access | Times Cited: 10
New technologies in therapeutic antibody development: The next frontier for treating infectious diseases
Sheila M. Keating, Brett W. Higgins
Antiviral Research (2024) Vol. 227, pp. 105902-105902
Closed Access | Times Cited: 3
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
Ruth A Purcell, Robert M. Theisen, Kelly B. Arnold, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect
Timothy Tipoe, Sarah Fidler, John Frater
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 3, pp. 162-170
Closed Access | Times Cited: 10
Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure
Stella J. Berendam, Ashley N. Nelson, Bhrugu Yagnik, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
Thandeka Moyo-Gwete, Cathrine Scheepers, Zanele Makhado, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Antibody class-switching as a strategy to improve HIV-1 neutralization
Cathrine Scheepers, Simone I. Richardson, Thandeka Moyo-Gwete, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 11, pp. 979-988
Open Access | Times Cited: 9
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Avi Kenny, Janine van Duijn, One Dintwe, et al.
EBioMedicine (2024) Vol. 108, pp. 105320-105320
Closed Access | Times Cited: 1
Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions
Angela I. Schriek, David Falck, Manfred Wuhrer, et al.
Antiviral Research (2024), pp. 106015-106015
Open Access | Times Cited: 1
SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties
Craig Fenwick, Priscilla Turelli, Dongchun Ni, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
De novo antibody sequencing based on mass spectrometry
Weiwei Peng
(2024)
Open Access
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
Nigel Garrett, One Dintwe, Cynthia L. Monaco, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2024) Vol. 96, Iss. 4, pp. 350-360
Open Access
Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility
Kemin Tan, Junjian Chen, Yu Kaku, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
Thandeka Moyo-Gwete, Cathrine Scheepers, Zanele Makhado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
The Impact of Pathogen Reduction on Total IgG and IgG Subclass Profiles of Convalescent Plasma
Tomasz Wasiluk, Magdalena Sredzinska, Anna Rogowska, et al.
Transfusion Medicine and Hemotherapy (2023), pp. 1-6
Open Access
Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility
Kemin Tan, Junjian Chen, Yu Kaku, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access
Super early treatment for HIV acquired in utero
Philippe Van de Perre, Penny L. Moore
The Lancet HIV (2023) Vol. 11, Iss. 1, pp. e3-e4
Closed Access
Page 1

Scroll to top